$ACXP

Acurx Pharmaceuticals, Inc.

CIK:0001736243|SEC Filings

CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
CONDENSED INTERIM STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
OPERATING EXPENSES
Research and Development	$ 1,071,536	$ 524,210	$ 1,413,004	$ 1,123,009
General and Administrative	1,235,692	1,745,473	2,610,215	3,323,156
TOTAL OPERATING EXPENSES	2,307,228	2,269,683	4,023,219	4,446,165
OPERATING LOSS	(2,307,228)	(2,269,683)	(4,023,219)	(4,446,165)
OTHER INCOME
Interest Income	53,055	23,404	88,064	50,693
NET LOSS	$ (2,254,173)	$ (2,246,279)	$ (3,935,155)	$ (4,395,472)
LOSS PER SHARE
Basic net loss per common share	$ (0.53)	$ (1.89)	$ (1.13)	$ (4.01)
Diluted net loss per common share	$ (0.53)	$ (1.89)	$ (1.13)	$ (4.01)
Weighted average common shares outstanding basic	4,259,540	1,190,266	3,493,244	1,096,620
Weighted average common shares outstanding diluted	4,259,540	1,190,266	3,493,244	1,096,620

CONDENSED INTERIM STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
CONDENSED INTERIM STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2026	Jun. 30, 2025
Cash Flows from Operating Activities:
Net Loss	$ (3,935,155)	$ (4,395,472)
Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:
Share-Based Compensation	458,824	657,814
Share-Based Payments to Vendors	141,999	196,260
(Increase)/Decrease in:
Other Receivable	(46,890)	10,919
Prepaid Expenses	(148,066)	46,601
Accounts Payable and Accrued Expenses	411,803	(238,195)
Net Cash Used in Operating Activities	(3,117,485)	(3,722,073)
Cash Flows from Financing Activities:
Proceeds from issuance of common stock in connection with equity line of credit purchase agreement, net of issuance costs	3,945,913	610,262
Proceeds from 2026 April Registered Direct Offering, net of issuance costs	2,271,858
Proceeds from 2025 March Registered Direct Offering, net of issuance costs		889,420
Proceeds from 2025 January Registered Direct Offering, net of issuance costs		2,099,253
Proceeds from 2025 Warrant Exercise, net of issuance costs		2,480,553
Net Cash Provided by Financing Activities	6,217,771	6,079,488
Net Increase in Cash	3,100,286	2,357,415
Cash at Beginning of Period	7,556,100	3,706,713
Cash at End of Period	$ 10,656,386	6,064,128
SUPPLEMENTAL DISCLOSURE OF NON-CASH OPERATING ACTIVITIES
Share-Based Compensation to settle accrued compensation (Note 5)		413,120
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES
2025 Equity Line of Credit Purchase Agreement costs (Commitment shares) (Note 4)		360,000
2025 Warrant Inducement Financing cost (Note 4)		4,636,869
2025 January Registered Direct Offering costs (Note 4)		85,419
2025 March Registered Direct Offering costs (Note 4)		$ 56,163

CONDENSED INTERIM BALANCE SHEETS - USD ($)	Jun. 30, 2026	Dec. 31, 2025
CURRENT ASSETS
Cash	$ 10,656,386	$ 7,556,100
Other Receivable	95,307	48,417
Prepaid Expenses	233,084	85,018
TOTAL ASSETS	10,984,777	7,689,535
CURRENT LIABILITIES
Accounts Payable and Accrued Expenses	2,832,746	2,420,943
TOTAL CURRENT LIABILITIES	2,832,746	2,420,943
TOTAL LIABILITIES	2,832,746	2,420,943
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY
Preferred Stock; $0.001 par value, 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2026 and December 31, 2025
Common Stock; $0.001 par value, 250,000,000 shares authorized, 4,683,253 and 2,348,113 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively	4,683	2,348
Additional Paid-In Capital	87,370,997	80,554,738
Accumulated Deficit	(79,223,649)	(75,288,494)
TOTAL SHAREHOLDERS' EQUITY	8,152,031	5,268,592
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 10,984,777	$ 7,689,535